Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis

Cancer Biomarkers

Volumn 15, Issue 1, 2015, Pages 65-78

  Liu, Qingyun ^a   Yu, Zubin ^a   Xiang, Ying ^a   Wu, Na ^a   Wu, Long ^a   Xu, Bin ^a   Wang, Liang ^b   Yang, Ping ^c   Li, Yafei ^a   Bai, Li ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Non small cell lung cancer; predictive factor; prognosis; thymidylate synthase

Indexed keywords

FLUOROURACIL; PEMETREXED; THYMIDYLATE SYNTHASE;

DRUG USE; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; DISEASE FREE SURVIVAL; ENZYMOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 84916933541     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140432     Document Type: Review

References (69)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C.Mathers and D.M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer 127 (2010), 2893-917.
2. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, J. von Pawel, U. Gatzemeier, T.C. Tsao, M. Pless, T. Muller, H.L. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn and P.A. Bunn, Jr., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol 22 (2004), 1589-97.
3. A. Spira and D.S. Ettinger, Multidisciplinary management of lung cancer, The New England journal of medicine 350 (2004), 379-92.
4. C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, M. Dusart, A. Haller, P. Lothaire, A.P. Meert, S. Noel, J.J. Lafitte and J.P. Sculier, The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis, Br J Cancer 92 (2005), 131-9.
5. L.X. Liu, X.Y. Shao, W. Gao, J.L. Bai, R.S. Wang, P.W. Huang, Y.M. Yin, P. Liu and Y.Q. Shu, The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer A Meta-Analysis of Published Data, Journal of Thoracic Oncology 5 (2010), 1922-1932.
6. C. Chung and M. Christianson, Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation, J Oncol Pharm Pract (2013).
7. K. Kaira, Y. Ohde, K. Nakagawa, T. Okumura, H. Murakami, T. Takahashi, H. Kondo, T. Nakajima, M. Endo and N. Yamamoto, Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma, Medical oncology (Northwood, London, England) 29 (2012), 1663-72.
8. E. Galvani, G.J. Peters and E. Giovannetti, Thymidylate synthase inhibitors for non-small cell lung cancer, Expert opinion on investigational drugs 20 (2011), 1343-1356.
9. M. Malet-Martino and R. Martino, Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review, Oncologist 7 (2002), 288-323.
10. H. Hochster, The role of pemetrexed in the treatment of colorectal cancer, Semin Oncol 29 (2002), 54-6.
11. H.S. Hochster, The role of pemetrexed in the treatment of gastrointestinal malignancy, Clin Colorectal Cancer 4 (2004), 190-5.
12. E. Chu, M.A. Callender, M.P. Farrell and J.C. Schmitz, Thymidylate synthase inhibitors as anticancer agents: from bench to bedside, Cancer Chemotherapy and Pharmacology 52(Suppl 1) (2003), S80-9.
13. M.G. Rose, M.P. Farrell and J.C. Schmitz, Thymidylate synthase: A critical target for cancer chemotherapy, Clin Colorectal Cancer 1 (2002), 220-9.
14. J. Nakano, C. Huang, D. Liu, D. Masuya, T. Nakashima, H. Yokomise,M. Ueno, H.Wada andM. Fukushima, Evaluations of biomarkers associated with 5-FU sensitivity for non-smallcell lung cancer patients postoperatively treated with UFT, Br J Cancer 95 (2006), 607-15.
15. P.P. Grimminger, P.M. Schneider, R. Metzger, D. Vallbohmer, A.H. Holscher, P.V. Danenberg and J. Brabender, Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer, Clin Lung Cancer 11 (2010), 328-34.
16. Z. Zheng, X. Li,M.J. Schell, T. Chen, D. Boulware, L. Robinson, E. Sommers and G. Bepler, Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer, Cancer 112 (2008), 2765-73.
17. M.W. Wynes, K. Konopa, S. Singh, B. Reyna-Asuncion, J. Ranger-Moore, A. Sternau, D.C. Christoph, R. Dziadziuszko, J. Jassem and F.R. Hirsch, Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 7 (2012), 982-92.
18. X. Wang, Y. Wang, J. Cheng and M. Ha, Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC, J Biomed Sci 20 (2013), 5.
19. J.M. Sun, J. Han, J.S. Ahn, K. Park and M.J. Ahn, Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy, J Thorac Oncol 6 (2011), 1392-9.
20. C.Y. Chen, Y.L. Chang, J.Y. Shih, J.W. Lin, K.Y. Chen, C.H. Yang, C.J. Yu and P.C. Yang, Thymidylate synthase and di hydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed, Lung Cancer 74 (2011), 132-8.
21. D.C. Christoph, B.R. Asuncion, B. Hassan, C. Tran, J.D. Maltzman, D.J. O'Shannessy, M.W. Wynes, T.C. Gauler, J. Wohlschlaeger, M. Hoiczyk, M. Schuler, W.E. Eberhardt and F.R. Hirsch, Significance of folate receptor alpha and thymidylate synthase protein expression in patients with nonsmall- cell lung cancer treated with pemetrexed, J Thorac Oncol 8 (2013), 19-30.
22. C.L. Huang, H. Yokomise, S. Kobayashi, M. Fukushima, S. Hitomi and H. Wada, Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy, Int J Oncol 17 (2000), 47-54.
23. T. Miyoshi, K. Kondo, H. Toba, M. Yoshida, H. Fujino, K. Kenzaki, S. Sakiyama, M. Takehisa and A. Tangoku, Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer, Anticancer Research 27 (2007), 2641-8.
24. D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe and S.B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA 283 (2000), 2008-12.
25. J. Little, L. Bradley, M.S. Bray, M. Clyne, J. Dorman, D.L. Ellsworth, J. Hanson, M. Khoury, J. Lau, T.R. O'Brien, N. Rothman, D. Stroup, E. Taioli, D. Thomas, H. Vainio, S. Wacholder and C. Weinberg, Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations, American journal of epidemiology 156 (2002), 300-10.
26. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett and M.R. Sydes, Practical methods for incorporating summary time-toevent data into meta-analysis, Trials 8 (2007), 16.
27. E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P.Meert, F. Vallot, J.J. Lafitte and J.P. Sculier, Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis, European Respiratory Journal 18 (2001), 705-19.
28. J.P. Higgins, S.G. Thompson, J.J. Deeks and D.G. Altman, Measuring inconsistency in meta-analyses, BMJ 327 (2003), 557-60.
29. M.H. Chang, J.S. Ahn, J. Lee, K.H. Kim, Y.H. Park, J. Han, M.J. Ahn and K. Park, The efficacy of pemetrexed as a thirdor fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer, Lung Cancer 69 (2010), 323-9.
30. S.H. Lee, K.B. Noh, J.S. Lee, E.J. Lee, K.H. Min, G.Y. Hur, S.Y. Lee, J.H. Kim, C. Shin, J.J. Shim, C.H. Kim, K.H. Kang and K.H. In, Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin, Lung Cancer (2013).
31. J.C. Duan, M.N. Wu, J. Zhao, T.T. An, L. Yang, H. Bai, Z.J. Wang, M.L. Zhuo, S.H. Wang, Y.Y. Wang, X.H. Liu and J. Wang, [Effect of pemetrexed plus platinum for chemotherapynaive advanced non-small cell lung cancer], Zhonghua Jie He He Hu Xi Za Zhi 35 (2012), 97-101.
32. S. Igawa, S. Ryuge, M.Wada, S. Otani, S. Maki, A. Takakura, K. Katono, J. Sasaki, Y. Sato and N. Masuda, Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression, Chemotherapy 58 (2012), 313-20.
33. K. Takezawa, I. Okamoto, W. Okamoto, M. Takeda, K. Sakai, S. Tsukioka, K. Kuwata, H. Yamaguchi, K. Nishio and K. Nakagawa, Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer, Br J Cancer 104 (2011), 1594-601.
34. C. Huang, D. Liu, D. Masuya, T. Nakashima, K. Kameyama, S. Ishikawa, M. Ueno, R. Haba and H. Yokomise, Clinical application of biological markers for treatments of resectable non-small-cell lung cancers, Br J Cancer 92 (2005), 1231-9.
35. Y. Shintani, M. Ohta, H. Hirabayashi, H. Tanaka, K. Iuchi, K. Nakagawa, H. Maeda, T. Kido, S. Miyoshi and H. Matsuda, New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction, Int J Cancer 104 (2003), 790-5.
36. T. Nakagawa, F. Tanaka, Y. Otake, K. Yanagihara, R. Miyahara, K. Matsuoka, T. Takata, T. Yamada, M. Fukushima and H.Wada, Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung, Lung Cancer 35 (2002), 165-70.
37. H. Shimokawa, H. Uramoto, T. Onitsuka, T. Iwata, M. Nakagawa, K. Ono and T. Hanagiri, TS expression predicts postoperative recurrence in adenocarcinoma of the lung, Lung cancer (Amsterdam, Netherlands) 72 (2011), 360-4.
38. H.Yokomise,D. Liu, S. Chang, T.Go, S. Ishikawa, N.Misaki and N. Nakashima, Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery, Anticancer Research 33 (2013), 1107-15.
39. Y. Nakagawa, T. Shimizu, N. Takahashi and S. Hashimoto, Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients, Mol Clin Oncol 1 (2013), 411-417.
40. M. Volm and J. Mattern, Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas, Anticancer Research 12 (1992), 2293-6.
41. M.C. Nicolson, D.A. Fennell, D. Ferry, K. O'Byrne, R. Shah, V. Potter, G. Skailes, S. Upadhyay, P. Taylor, V. Andre, T.S. Nguyen, S.P. Myrand, C. Visseren-Grul, M. Das and K.M. Kerr, Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous nonsmall- cell lung cancer in a prospective blinded assessment phase II clinical trial, J Thorac Oncol 8 (2013), 930-9.
42. S.M. Gadgeel, J.C. Ruckdeschel, B.B. Patel, A. Wozniak, A. Konski, M. Valdivieso, D. Hackstock, W. Chen, K. Belzer, A.M. Burger, L. Marquette and A. Turrisi, Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer, J Thorac Oncol 6 (2011), 927-33.
43. L.G. Navalgund, C. Rossana, A.J. Muench and L.F. Johnson, Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts, J Biol Chem 255 (1980), 7386-90.
44. B.C. Pestalozzi, C.J. McGinn, T.J. Kinsella, J.C. Drake, M.C. Glennon, C.J. Allegra and P.G. Johnston, Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells, British Journal of Cancer 71 (1995), 1151-7.
45. M. Derenzini, L.Montanaro, D. Trere, A. Chilla, P.L. Tazzari, F. Dall'Olio and D. Ofner, Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines, Mol Pathol 55 (2002), 310-4.
46. T. Nakagawa, Y. Otake, K. Yanagihara, R. Miyahara, S. Ishikawa, M. Fukushima, H. Wada and F. Tanaka, Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC), Lung Cancer 43 (2004), 145-149.
47. H.B. Hu, L. Kuang, X.M. Zeng, B. Li, E.Y. Liu and M.Z. Zhong, Predictive value of thymidylate synthase expression in gastric cancer: A systematic review with meta-analysis, Asian Pacific Journal of Cancer Prevention: APJCP 13 (2012), 261-7.
48. T. Yamachika, H. Nakanishi, K. Inada, T. Tsukamoto, T. Kato, M. Fukushima,M. Inoue andM. Tatematsu, A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance, Cancer 82 (1998), 70-7.
49. D. Edler, M. Hallström, P.G. Johnston, I. Magnusson, P. Ragnhammar and H. Blomgren, Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer, Clinical Cancer Research 6 (2000), 1378-1384.
50. M. Suzuki, S. Tsukagoshi, Y. Saga, M. Ohwada and I. Sato, Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer, Oncology 57 (1999), 50-54.
51. P.G. Johnston, E.R. Fisher, H.E. Rockette, B. Fisher, N. Wolmark, J.C. Drake, B.A. Chabner and C.J. Allegra, The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer, J Clin Oncol 12 (1994), 2640-7.
52. H.J. Lenz, C.G. Leichman, K.D. Danenberg, P.V. Danenberg, S. Groshen, H. Cohen, L. Laine, P. Crookes, H. Silberman, J. Baranda, Y. Garcia, J. Li and L. Leichman, Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival, Journal of Clinical Oncology: Ifficial Journal of the American Society of Clinical Oncology 14 (1996), 176-82.
53. D.H. Harpole, Jr., M.B. Moore, J.E. Herndon, 2nd, T. Aloia, T.A. D'Amico, T. Sporn, A. Parr, I. Linoila and C. Allegra, The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer, Clin Cancer Res 7 (2001), 562-9.
54. C. Shih, V.J. Chen, L.S. Gossett, S.B. Gates, W.C. MacKellar, L.L. Habeck, K.A. Shackelford, L.G.Mendelsohn, D.J. Soose and V.F. Patel, LY231514, a pyrrolo [2, 3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes, Cancer Research 57 (1997), 1116-1123.
55. A.R. Hanauske, V. Chen, P. Paoletti and C. Niyikiza, Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors, Oncologist 6 (2001), 363-73.
56. G. Grindey, C. Shih, C. Barnett, H. Pearce, J. Engelhardt, G. Todd, S. Rinzel, J. Worzalla, L. Gossett and T. Everson, LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS), in: Proc Am Assoc Cancer Res, 1992, pp. 411.
57. A.-R. Hanauske, U. Eismann, O. Oberschmidt, H. Pospisil, S. Hoffmann, H. Hanauske-Abel, D. Ma, V. Chen, P. Paoletti and C. Niyikiza, In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression, Investigational New Drugs 25 (2007), 417-23.
58. J. Sigmond, H.H.J. Backus, D. Wouters, O.H. Temmink, G. Jansen and G.J. Peters, Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) inWiDr human colon cancer cells is associated with thymidylate synthase overexpression, Biochemical Pharmacology 66 (2003), 431-8.
59. E. Giovannetti, V.Mey, S. Nannizzi, G. Pasqualetti, L.Marini, M. Del Tacca and R. Danesi, Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells, Mol Pharmacol 68 (2005), 110-8.
60. H. Ozasa, T. Oguri, T. Uemura, M. Miyazaki, K. Maeno, S. Sato and R. Ueda, Significance of thymidylate synthase for resistance to pemetrexed in lung cancer, Cancer Sci 101 (2010), 161-6.
61. H.L. Gomez, S.L. Santillana, C.S. Vallejos, R. Velarde, J. Sanchez, X. Wang, N.L. Bauer, R.D. Hockett, V.J. Chen and C. Niyikiza, A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression, Clinical Cancer Research 12 (2006), 832-838.
62. W.J. Li, H. Jiang, X.J. Fang, H.L. Ye, M.H. Liu, Y.W. Liu, Q. Chen, L. Zhang, J.Y. Zhang, C.L. Yuan and Q.Y. Zhang, Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced nonsmall cell lung cancer patients treated with pemetrexed-based chemotherapy, Oncology Letters 5 (2013), 1165-1170.
63. D. Kasai, H. Ozasa, T. Oguri, M. Miyazaki, T. Uemura, O. Takakuwa, E. Kunii, H. Ohkubo, K. Maeno and A. Niimi, Thymidylate Synthase Gene Copy Number as a Predictive Marker for Response to Pemetrexed Treatment of Lung Adenocarcinoma, Anticancer Research 33 (2013), 1935-1940.
64. A. Lima, R. Azevedo, H. Sousa, V. Seabra and R. Medeiros, Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics, Pharmacogenomics 14 (2013), 1337-51.
65. H.J. Lenz, C.G. Leichman, K.D. Danenberg, P.V. Danenberg, S. Groshen, H. Cohen, L. Laine, P. Crookes, H. Silberman, J. Baranda, Y. Garcia, J. Li and L. Leichman, Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival, Journal of Clinical Oncology 14 (1996), 176-82.
66. P.G. Johnston, H.J. Lenz, C.G. Leichman, K.D. Danenberg, C.J. Allegra, P.V. Danenberg and L. Leichman, Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors, Cancer Res 55 (1995), 1407-12.
67. Y. Liu, T.-J. Yin, R. Zhou, S. Zhou, L. Fan and R.-G. Zhang, Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for nonsmall- cell lung cancer: a systemic review and meta-analysis, Cancer Chemotherapy and Pharmacology (2013), 1-8.
68. T. Wang, C.C. Pan, J.R. Yu, Y. Long, X.H. Cai, X. De Yin, L.Q. Hao and L.L. Luo, Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: AMeta-Analysis, PLoS One 8 (2013), e74284.
69. L. Wang, R. Wang, Y. Pan, Y. Sun, J. Zhang and H. Chen, The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: A metaanalysis, BMC Cancer 14 (2014), 205.